MX345435B - Composicion farmaceutica para la administracion oral con disolucion y/o absorcion mejorada. - Google Patents

Composicion farmaceutica para la administracion oral con disolucion y/o absorcion mejorada.

Info

Publication number
MX345435B
MX345435B MX2015003410A MX2015003410A MX345435B MX 345435 B MX345435 B MX 345435B MX 2015003410 A MX2015003410 A MX 2015003410A MX 2015003410 A MX2015003410 A MX 2015003410A MX 345435 B MX345435 B MX 345435B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
oral administration
absorbency
acid
improved elution
Prior art date
Application number
MX2015003410A
Other languages
English (en)
Other versions
MX2015003410A (es
Inventor
Takashi Suefuji
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2015003410A publication Critical patent/MX2015003410A/es
Publication of MX345435B publication Critical patent/MX345435B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

Esta invención se refiere a una composición farmacéutica para la administración oral que comprende 4-((1-metilpirro-2-iI)-carbonil) -N-(4-(4-morfoIin-1-iI-carboniIpiperidin-1-il)-feniI)-1- piperazinacarboxamida, una sal de la misma o un solvato de la misma, como un ingrediente farmacéutico activo; y por lo menos un aditivo de ácido seleccionado del grupo formado por ácido adípico, ácido succínico, ácido fumárico, ácido L-aspártico y ácido L-glutámico.
MX2015003410A 2012-09-19 2013-09-18 Composicion farmaceutica para la administracion oral con disolucion y/o absorcion mejorada. MX345435B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012205681 2012-09-19
PCT/JP2013/075157 WO2014046129A1 (ja) 2012-09-19 2013-09-18 溶出性及び／又は吸収性が改善された経口投与用医薬組成物

Publications (2)

Publication Number Publication Date
MX2015003410A MX2015003410A (es) 2015-06-04
MX345435B true MX345435B (es) 2017-01-30

Family

ID=50341439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003410A MX345435B (es) 2012-09-19 2013-09-18 Composicion farmaceutica para la administracion oral con disolucion y/o absorcion mejorada.

Country Status (20)

Country Link
US (1) US9555115B2 (es)
EP (1) EP2898886B1 (es)
JP (1) JP5791817B2 (es)
KR (1) KR101609105B1 (es)
CN (1) CN104640547B (es)
AU (1) AU2013319118B2 (es)
BR (1) BR112015005489B1 (es)
CA (1) CA2884731C (es)
DK (1) DK2898886T3 (es)
ES (1) ES2622585T3 (es)
HK (1) HK1207969A1 (es)
HU (1) HUE032635T2 (es)
MX (1) MX345435B (es)
MY (1) MY183976A (es)
PL (1) PL2898886T3 (es)
PT (1) PT2898886T (es)
RU (1) RU2589701C1 (es)
SG (1) SG11201501043TA (es)
TW (1) TWI536992B (es)
WO (1) WO2014046129A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI707851B (zh) * 2015-09-17 2020-10-21 日商大鵬藥品工業股份有限公司 哌嗪化合物的新穎結晶

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
JP4292588B2 (ja) * 1997-01-31 2009-07-08 日産化学工業株式会社 ピリダジノン化合物類の経口製剤
JP3797764B2 (ja) 1997-10-01 2006-07-19 エーザイ株式会社 光安定化組成物
NZ526471A (en) * 2000-12-21 2005-08-26 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
EP1397160A1 (en) 2001-04-30 2004-03-17 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
JP2003252762A (ja) * 2001-12-25 2003-09-10 Takeda Chem Ind Ltd 酸配合製剤
US20040137052A1 (en) 2001-12-25 2004-07-15 Yoshihiro Uchiyama Acid-containing preparations
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP4572293B2 (ja) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 ピモベンダン経口投与製剤
MX370905B (es) * 2006-08-31 2020-01-09 Adare Pharmaceuticals Inc Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
BRPI0809522A2 (pt) 2007-03-28 2014-10-14 Takeda Pharmaceutical Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.
JP5343845B2 (ja) 2007-05-21 2013-11-13 東レ株式会社 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
JP2011522006A (ja) 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 新規化合物ｖ
MX2011000757A (es) 2008-07-28 2011-02-24 Takeda Pharmaceutical Composicion farmaceutica.
US8977428B2 (en) 2009-03-06 2015-03-10 Toyota Jidosha Kabushiki Kaisha Vehicle drive support device
CN102341385B (zh) * 2009-03-09 2014-01-15 大鹏药品工业株式会社 能够抑制***素d合酶的哌嗪化合物

Also Published As

Publication number Publication date
AU2013319118A1 (en) 2015-03-12
CN104640547A (zh) 2015-05-20
EP2898886A1 (en) 2015-07-29
HUE032635T2 (en) 2017-10-30
PL2898886T3 (pl) 2017-06-30
RU2589701C1 (ru) 2016-07-10
US20150297722A1 (en) 2015-10-22
TW201414476A (zh) 2014-04-16
MY183976A (en) 2021-03-17
EP2898886A4 (en) 2016-04-27
ES2622585T3 (es) 2017-07-06
CA2884731C (en) 2016-11-01
BR112015005489A2 (pt) 2017-07-04
SG11201501043TA (en) 2015-04-29
JP5791817B2 (ja) 2015-10-07
DK2898886T3 (en) 2017-03-27
CA2884731A1 (en) 2014-03-27
TWI536992B (zh) 2016-06-11
AU2013319118B2 (en) 2016-03-03
HK1207969A1 (en) 2016-02-19
US9555115B2 (en) 2017-01-31
PT2898886T (pt) 2017-03-23
BR112015005489B1 (pt) 2022-07-12
KR101609105B1 (ko) 2016-04-04
EP2898886B1 (en) 2017-02-15
CN104640547B (zh) 2017-07-11
WO2014046129A1 (ja) 2014-03-27
JPWO2014046129A1 (ja) 2016-08-18
KR20150056827A (ko) 2015-05-27
MX2015003410A (es) 2015-06-04

Similar Documents

Publication Publication Date Title
IL253119B (en) 4-{4[({[4-chloro-3-(trifluoroacetyl)phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate and preparations including it
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
PH12015502116A1 (en) Biaryl amide compounds as kinase inhibitors
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
NZ721298A (en) Pharmaceutical compositions comprising azd9291
MX2015010971A (es) Derivado novedoso de pirazol.
MX2015017345A (es) Compuestos para tratar atrofia muscular espinal.
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
IL223543A (en) Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition
MX2011012344A (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoi co y acido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino) butilo.
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
PH12015501096A1 (en) Composition for immediate and extended release
GEP20135950B (en) New compositions containing 1-[2-(2,4-dimethyl-phenylsulfa-nyl)-phenyl]piperazine
MX2015011614A (es) Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia.
EP3103453A4 (en) Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
MY174149A (en) Composition for oral cavity
BR112012020629A2 (pt) forma cristalina, e, método para a terapia de um distúrbio
PH12016500577A1 (en) Piperazine derivatives and the use thereof as medicament
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
GEP201606566B (en) Isoxazolidine derivatives
MY169266A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT

Legal Events

Date Code Title Description
FG Grant or registration